TY - JOUR AU - Siegel, R. AU - Naishadham, D. AU - Jemal, A. PY - 2012 DA - 2012// TI - Cancer statistics, 2012 JO - CA: Cancer J Clin VL - 62 ID - Siegel2012 ER - TY - STD TI - SEER Cancer Statistics Review, 1975–2010 [Internet]. Bethesda, MD.: National Cancer Institute; based on November 2012 SEER data submission, posted to the SEER web site, April 2013. Available from: http://seer.cancer.gov/csr/1975_2010/. Accessed 29 Dec 2013. UR - http://seer.cancer.gov/csr/1975_2010/ ID - ref2 ER - TY - JOUR AU - Bois, A. AU - Lück, H. AU - Meier, W. AU - Adams, H. AU - Möbus, V. AU - Costa, S. PY - 2003 DA - 2003// TI - A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer JO - J Natl Cancer Inst VL - 95 UR - https://doi.org/10.1093/jnci/djg036 DO - 10.1093/jnci/djg036 ID - Bois2003 ER - TY - JOUR AU - Piccart, M. J. AU - Bertelsen, K. AU - James, K. AU - Cassidy, J. AU - Mangioni, C. AU - Simonsen, E. PY - 2000 DA - 2000// TI - Randomized intergroup trial of cisplatin–paclitaxel versus cisplatin–cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results JO - J Natl Cancer Inst VL - 92 UR - https://doi.org/10.1093/jnci/92.9.699 DO - 10.1093/jnci/92.9.699 ID - Piccart2000 ER - TY - JOUR AU - McGuire, W. P. AU - Hoskins, W. J. AU - Brady, M. F. AU - Kucera, P. R. AU - Partridge, E. E. AU - Look, K. Y. PY - 1996 DA - 1996// TI - Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer JO - N Engl J Med VL - 34 UR - https://doi.org/10.1056/NEJM199601043340101 DO - 10.1056/NEJM199601043340101 ID - McGuire1996 ER - TY - JOUR AU - Cannistra, S. A. PY - 2004 DA - 2004// TI - Cancer of the ovary JO - N Engl J Med VL - 351 UR - https://doi.org/10.1056/NEJMra041842 DO - 10.1056/NEJMra041842 ID - Cannistra2004 ER - TY - JOUR AU - Lister-Sharp, D. AU - McDonagh, M. AU - Khan, K. AU - Kleijnen, J. PY - 2000 DA - 2000// TI - A rapid and systematic review of the effectiveness and cost-effectiveness of the taxanes used in the treatment of advanced breast and ovarian cancer JO - Health Technol Assess VL - 4 ID - Lister-Sharp2000 ER - TY - JOUR AU - Cannistra, S. A. PY - 2002 DA - 2002// TI - Is there a “best” choice of second-line agent in the treatment of recurrent, potentially platinum-sensitive ovarian cancer? JO - J Clin Oncol VL - 20 ID - Cannistra2002 ER - TY - JOUR AU - Altomare, D. A. AU - Wang, H. Q. AU - Skele, K. L. AU - Rienzo, A. AU - Klein-Szanto, A. J. AU - Godwin, A. K. PY - 2004 DA - 2004// TI - AKT and mTOR phosphorylation is frequently detected in ovarian cancer and can be targeted to disrupt ovarian tumor cell growth JO - Oncogene VL - 23 UR - https://doi.org/10.1038/sj.onc.1207721 DO - 10.1038/sj.onc.1207721 ID - Altomare2004 ER - TY - JOUR AU - Benedetti, V. AU - Perego, P. AU - Luca Beretta, G. AU - Corna, E. AU - Tinelli, S. AU - Righetti, S. C. PY - 2008 DA - 2008// TI - Modulation of survival pathways in ovarian carcinoma cell lines resistant to platinum compounds JO - Mol Cancer Ther VL - 7 UR - https://doi.org/10.1158/1535-7163.MCT-07-0450 DO - 10.1158/1535-7163.MCT-07-0450 ID - Benedetti2008 ER - TY - JOUR AU - Reles, A. AU - Wen, W. H. AU - Schmider, A. AU - Gee, C. AU - Runnebaum, I. B. AU - Kilian, U. PY - 2001 DA - 2001// TI - Correlation of p53 mutations with resistance to platinum-based chemotherapy and shortened survival in ovarian cancer JO - Clin Cancer Res VL - 7 ID - Reles2001 ER - TY - JOUR AU - Lawlor, M. A. AU - Alessi, D. R. PY - 2001 DA - 2001// TI - PKB/AKT: a key mediator of cell proliferation, survival and insulin responses? JO - J Cell Sci VL - 114 ID - Lawlor2001 ER - TY - JOUR AU - LoPiccolo, J. PY - 2007 DA - 2007// TI - Targeting AKT in cancer therapy JO - Anticancer Drugs VL - 18 ID - LoPiccolo2007 ER - TY - JOUR AU - Fraser, M. AU - Bai, T. AU - Tsang, B. K. PY - 2008 DA - 2008// TI - AKT promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function JO - Int J Cancer VL - 122 UR - https://doi.org/10.1002/ijc.23086 DO - 10.1002/ijc.23086 ID - Fraser2008 ER - TY - JOUR AU - Bellacosa, A. AU - Feo, D. AU - Godwin, A. K. AU - Bell, D. W. AU - Cheng, J. Q. AU - Altomare, D. A. PY - 1995 DA - 1995// TI - Molecular alterations of the AKT2 oncogene in ovarian and breast carcinomas JO - Int J Cancer VL - 64 UR - https://doi.org/10.1002/ijc.2910640412 DO - 10.1002/ijc.2910640412 ID - Bellacosa1995 ER - TY - JOUR AU - Yuan, Z. Q. AU - Sun, M. AU - Feldman, R. AU - Wang, G. AU - Ma, X. AU - Jiang, C. PY - 2000 DA - 2000// TI - Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/AKT pathway in human ovarian cancer JO - Oncogene VL - 19 UR - https://doi.org/10.1038/sj.onc.1203598 DO - 10.1038/sj.onc.1203598 ID - Yuan2000 ER - TY - JOUR AU - DeFeo-Jones, D. AU - Barnett, S. F. AU - Fu, S. AU - Hancock, P. J. AU - Haskell, K. M. AU - Leander, K. R. PY - 2005 DA - 2005// TI - Tumor cell sensitization to apoptotic stimuli by selective inhibition of specific AKT/PKB family members JO - Mol Cancer Ther VL - 4 ID - DeFeo-Jones2005 ER - TY - STD TI - Yan L. Abstract #DDT01-1: MK-2206: A potent oral allosteric AKT inhibitor. 2009 American Association for Cancer Research; Cancer Res. 2014;69(9 Supplement). ID - ref18 ER - TY - JOUR AU - Cherrin, C. AU - Haskell, K. AU - Howell, B. AU - Jones, R. AU - Leander, K. AU - Robinson, R. PY - 2010 DA - 2010// TI - An allosteric AKT inhibitor effectively blocks AKT signaling and tumor growth with only transient effects on glucose and insulin levels in vivo JO - Cancer Biol Ther VL - 9 UR - https://doi.org/10.4161/cbt.9.7.11100 DO - 10.4161/cbt.9.7.11100 ID - Cherrin2010 ER - TY - JOUR AU - Hirai, H. AU - Sootome, H. AU - Nakatsuru, Y. AU - Miyama, K. AU - Taguchi, S. AU - Tsujioka, K. PY - 2010 DA - 2010// TI - MK-2206, an allosteric AKT inhibitor, enhances antitumor efficacy by standard chemotherapeutic agents or molecular targeted drugs in vitro and in vivo JO - Mol Cancer Ther VL - 9 UR - https://doi.org/10.1158/1535-7163.MCT-09-1012 DO - 10.1158/1535-7163.MCT-09-1012 ID - Hirai2010 ER - TY - JOUR AU - Khanna, K. K. AU - Jackson, S. PY - 2001 DA - 2001// TI - DNA double-strand breaks: signaling, repair and the cancer connection JO - Nat Genet VL - 27 UR - https://doi.org/10.1038/85798 DO - 10.1038/85798 ID - Khanna2001 ER - TY - JOUR AU - Kennedy, R. D. AU - Quinn, J. E. AU - Mullan, P. B. AU - Johnston, P. G. AU - Harkin, D. P. PY - 2004 DA - 2004// TI - The Role of BRCA1 in the Cellular Response to Chemotherapy JO - J Natl Cancer Inst VL - 96 UR - https://doi.org/10.1093/jnci/djh312 DO - 10.1093/jnci/djh312 ID - Kennedy2004 ER - TY - JOUR AU - Horiuchi, A. PY - 2006 DA - 2006// TI - BRCA1 expression is an important biomarker for chemosensitivity: suppression of BRCA1 increases the apoptosis via up-regulation of p53 and p21 during cisplatin treatment in ovarian cancer cells JO - Biomark Insights. VL - 1 ID - Horiuchi2006 ER - TY - JOUR AU - Nojima, K. AU - Hochegger, H. AU - Saberi, A. AU - Fukushima, T. AU - Kikuchi, K. AU - Yoshimura, M. PY - 2005 DA - 2005// TI - Multiple repair pathways mediate tolerance to chemotherapeutic cross-linking agents in vertebrate cells JO - Cancer Res VL - 65 UR - https://doi.org/10.1158/0008-5472.CAN-05-1214 DO - 10.1158/0008-5472.CAN-05-1214 ID - Nojima2005 ER - TY - JOUR AU - Tutt, A. N. J. AU - Lord, C. J. AU - McCabe, N. AU - Farmer, H. AU - Turner, N. AU - Martin, N. M. PY - 2005 DA - 2005// TI - Exploiting the DNA repair defect in BRCA mutant cells in the design of new therapeutic strategies for cancer JO - Cold Spring Harbor Symp Quant Biol. VL - 70 UR - https://doi.org/10.1101/sqb.2005.70.012 DO - 10.1101/sqb.2005.70.012 ID - Tutt2005 ER - TY - JOUR AU - Swisher, E. M. AU - Sakai, W. AU - Karlan, B. Y. AU - Wurz, K. AU - Urban, N. AU - Taniguchi, T. PY - 2008 DA - 2008// TI - Secondary BRCA1 mutations in BRCA1-mutated ovarian carcinomas with platinum resistance JO - Cancer Res VL - 68 UR - https://doi.org/10.1158/0008-5472.CAN-08-0088 DO - 10.1158/0008-5472.CAN-08-0088 ID - Swisher2008 ER - TY - JOUR AU - Ashworth, A. PY - 2008 DA - 2008// TI - A synthetic lethal therapeutic approach: poly (ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair JO - J Clin Oncol VL - 26 UR - https://doi.org/10.1200/JCO.2008.16.0812 DO - 10.1200/JCO.2008.16.0812 ID - Ashworth2008 ER - TY - JOUR AU - Szanto, A. AU - Hellebrand, E. E. AU - Bognar, Z. AU - Tucsek, Z. AU - Szabo, A. AU - Gallyas, F. PY - 2009 DA - 2009// TI - PARP-1 inhibition-induced activation of PI-3-kinase-AKT pathway promotes resistance to taxol JO - Biochem Pharmacol VL - 77 UR - https://doi.org/10.1016/j.bcp.2009.01.008 DO - 10.1016/j.bcp.2009.01.008 ID - Szanto2009 ER - TY - JOUR AU - Xiang, T. AU - Ohashi, A. AU - Huang, Y. AU - Pandita, T. K. AU - Ludwig, T. AU - Powell, S. N. PY - 2008 DA - 2008// TI - Negative regulation of AKT activation by BRCA1 JO - Cancer Res VL - 68 UR - https://doi.org/10.1158/0008-5472.CAN-08-3009 DO - 10.1158/0008-5472.CAN-08-3009 ID - Xiang2008 ER - TY - JOUR AU - Moro, L. AU - Arbini, A. A. AU - Marra, E. AU - Greco, M. PY - 2007 DA - 2007// TI - Constitutive activation of MAPK/ERK inhibits prostate cancer cell proliferation through upregulation of BRCA2 JO - Int J Oncol VL - 30 ID - Moro2007 ER - TY - JOUR AU - Plo, I. AU - Laulier, C. AU - Gauthier, L. AU - Lebrun, F. AU - Calvo, F. AU - Lopez, B. S. PY - 2008 DA - 2008// TI - AKT1 inhibits homologous recombination by inducing cytoplasmic retention of BRCA1 and RAD51 JO - Cancer Res VL - 68 UR - https://doi.org/10.1158/0008-5472.CAN-08-0861 DO - 10.1158/0008-5472.CAN-08-0861 ID - Plo2008 ER - TY - STD TI - Ratner E, Sartorelli A, Lin Z. Poly (ADP-ribose) polymerase inhibitors: on the horizon of tailored and personalized therapies for epithelial ovarian cancer. Curr Opin Oncol. 2012;(Epub ahead of print) ID - ref32 ER - TY - JOUR AU - Lin, Z. P. AU - Belcourt, M. F. AU - Cory, J. G. AU - Sartorelli, A. C. PY - 2004 DA - 2004// TI - Stable suppression of the R2 subunit of ribonucleotide reductase by R2-targeted short interference RNA sensitizes p53(−/−) HCT-116 colon cancer cells to DNA-damaging agents and ribonucleotide reductase inhibitors JO - J Biol Chem VL - 279 UR - https://doi.org/10.1074/jbc.M402056200 DO - 10.1074/jbc.M402056200 ID - Lin2004 ER - TY - JOUR AU - Lin, Z. P. AU - Ratner, E. S. AU - Whicker, M. E. AU - Lee, Y. AU - Sartorelli, A. C. PY - 2014 DA - 2014// TI - Triapine disrupts CtIP-mediated homologous recombination repair and sensitizes ovarian cancer cells to PARP and topoisomerase inhibitors JO - Mol Cancer Res VL - 12 UR - https://doi.org/10.1158/1541-7786.MCR-13-0480 DO - 10.1158/1541-7786.MCR-13-0480 ID - Lin2014 ER - TY - JOUR AU - Langdon, S. P. AU - Lawrie, S. S. AU - Hay, F. G. AU - Hawkes, M. M. AU - McDonald, A. AU - Hayward, I. P. PY - 1988 DA - 1988// TI - Characterization and properties of nine human ovarian adenocarcinoma cell lines JO - Cancer Res VL - 48 ID - Langdon1988 ER - TY - JOUR AU - Cooke, S. L. AU - Ng, C. K. Y. AU - Melnyk, N. AU - Garcia, M. J. AU - Hardcastle, T. AU - Temple, J. PY - 2010 DA - 2010// TI - Genomic analysis of genetic heterogeneity and evolution in high-grade serous ovarian carcinoma JO - Oncogene VL - 29 UR - https://doi.org/10.1038/onc.2010.245 DO - 10.1038/onc.2010.245 ID - Cooke2010 ER - TY - JOUR AU - Chou, T. C. PY - 1984 DA - 1984// TI - Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors JO - Adv Enzyme Regul. VL - 22 UR - https://doi.org/10.1016/0065-2571(84)90007-4 DO - 10.1016/0065-2571(84)90007-4 ID - Chou1984 ER - TY - JOUR AU - Goldfarb, S. B. AU - Kashlan, O. B. AU - Watkins, J. N. AU - Suaud, L. AU - Yan, W. AU - Kleyman, T. R. PY - 2006 DA - 2006// TI - Differential effects of Hsc70 and Hsp70 on the intracellular trafficking and functional expression of epithelial sodium channels JO - Proc Natl Acad Sci USA VL - 103 UR - https://doi.org/10.1073/pnas.0507903103 DO - 10.1073/pnas.0507903103 ID - Goldfarb2006 ER - TY - JOUR AU - Zhu, Z. AU - Ramos, J. AU - Kampa, K. AU - Adimoolam, S. AU - Sirisawad, M. AU - Yu, Z. PY - 2005 DA - 2005// TI - Control of ASPP2/53BP2L protein levels by proteasomal degradation modulates p53 apoptotic function JO - J Biol Chem VL - 280 UR - https://doi.org/10.1074/jbc.M503736200 DO - 10.1074/jbc.M503736200 ID - Zhu2005 ER - TY - JOUR AU - Wullschleger, S. AU - Loewith, R. AU - Hall, M. N. PY - 2006 DA - 2006// TI - TOR signaling in growth and metabolism JO - Cell VL - 124 UR - https://doi.org/10.1016/j.cell.2006.01.016 DO - 10.1016/j.cell.2006.01.016 ID - Wullschleger2006 ER - TY - JOUR AU - Zhang, J. AU - Zhang, L. AU - Shen, L. AU - Xu, X. AU - Yu, H. PY - 2013 DA - 2013// TI - Regulation of AKT gene expression by cisplatin JO - Oncol Lett VL - 5 ID - Zhang2013 ER - TY - JOUR AU - Jacinto, E. AU - Facchinetti, V. AU - Liu, D. AU - Soto, N. AU - Wei, S. AU - Jung, S. Y. PY - 2006 DA - 2006// TI - SIN1/MIP1 maintains rictor-mTOR complex integrity and regulates AKT phosphorylation and substrate specificity JO - Cell VL - 127 UR - https://doi.org/10.1016/j.cell.2006.08.033 DO - 10.1016/j.cell.2006.08.033 ID - Jacinto2006 ER - TY - JOUR AU - Dedes, K. J. PY - 2011 DA - 2011// TI - Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations JO - Cell Cycle VL - 10 UR - https://doi.org/10.4161/cc.10.8.15273 DO - 10.4161/cc.10.8.15273 ID - Dedes2011 ER - TY - JOUR AU - Ledermann, J. AU - Harter, P. AU - Gourley, C. AU - Friedlander, M. AU - Vergote, I. AU - Rustin, G. PY - 2012 DA - 2012// TI - Olaparib maintenance therapy in platinum-sensitive relapsed ovarian cancer JO - N Engl J Med VL - 366 UR - https://doi.org/10.1056/NEJMoa1105535 DO - 10.1056/NEJMoa1105535 ID - Ledermann2012 ER - TY - JOUR AU - Haber, J. E. PY - 1999 DA - 1999// TI - DNA recombination: the replication connection JO - Trends Biochem Sci VL - 24 UR - https://doi.org/10.1016/S0968-0004(99)01413-9 DO - 10.1016/S0968-0004(99)01413-9 ID - Haber1999 ER - TY - JOUR AU - Siddik, Z. S. PY - 2003 DA - 2003// TI - Cisplatin: mode of cytotoxic action and molecular basis of resistance JO - Oncogene VL - 22 UR - https://doi.org/10.1038/sj.onc.1206933 DO - 10.1038/sj.onc.1206933 ID - Siddik2003 ER - TY - JOUR AU - Chou, T. PY - 2010 DA - 2010// TI - Drug combination studies and their synergy quantification using the Chou-Talalay method JO - Cancer Res VL - 70 UR - https://doi.org/10.1158/0008-5472.CAN-09-1947 DO - 10.1158/0008-5472.CAN-09-1947 ID - Chou2010 ER -